When does Eliquis’ patent actually expire in 2028?
Eliquis (apixaban) has multiple patents and different “clock” dates tied to exclusivity, filings, and potential patent term adjustments. Based on publicly tracked patent information, key Eliquis patent expirations are expected around 2028, with additional related patents potentially extending or triggering new regulatory exclusivity timing depending on country and the specific patent listed.
For a consolidated view of Eliquis patent expiry dates (including the specific patent numbers and projected end dates), see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/eliquis-apixaban/
Why are there multiple Eliquis expiry dates instead of one?
Patent expiry isn’t one single date for brands like Eliquis because each patent can cover different elements, such as formulation, manufacturing process, dosing forms, or specific method claims. As those separate patents approach the end of their terms, generic or biosimilar competitors still have to navigate which patents remain enforceable at the time of entry and whether exclusivity protections block approval.
That is why commercial “expiry in 2028” can coexist with other later or earlier patent end dates listed for the same product.
Does “patent expiry in 2028” mean generics can launch immediately?
Not necessarily. Even if a major patent is scheduled to expire in 2028, launch timing can be delayed by:
- remaining patents with later expiry dates,
- regulatory exclusivity that goes beyond patent terms,
- ongoing litigation or “carve-outs” where only certain claims are cleared,
- differences between a patent expiry date and the date the regulator can approve a product.
A patent expiry date is therefore best read as a key milestone that affects the probability of entry, not a guarantee of immediate market launch.
What to check if you need the exact legal/market date for your situation
If you’re trying to estimate when a generic could enter a specific market (for example, the U.S. versus the EU), you typically need to match:
- the relevant country’s patent schedule,
- the specific patent(s) being asserted or cleared,
- any regulatory exclusivity listed for apixaban in that jurisdiction.
DrugPatentWatch.com’s country-by-country patent tracking is often the fastest way to identify which patents are projected to end around 2028 and which ones might extend beyond that.
Source to use for the 2028 date(s)
DrugPatentWatch.com maintains an updated listing of apixaban (Eliquis) patents and projected expiry timelines, including the entries that point to 2028.
Sources:
1. https://www.drugpatentwatch.com/p/eliquis-apixaban/